Navigation Links
OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
Date:10/4/2010

BOTHELL, WA and VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that management of OncoGenex will present at the 9th Annual BIO Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT at The Palace Hotel in San Francisco, CA.

Live webcasts from this conference will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Webcast replays will be available approximately two hours after the calls are completed and will be archived for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limit
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
4. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
5. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
6. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
7. OncoGenex Reports Third Quarter Financial Results
8. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
9. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The In Silico Drug Discovery ... be featured at the conference, which takes place at ... 3 and 4, 2014. Researchers, students, drug developers, business ... the following: KEYNOTE SPEAKERS ... Skaggs School of Pharmacy Drug Discovery with ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A ... occurring microorganisms such as bacteria, fungi, and algae ... water, methane, biomass, inorganic compounds, carbon dioxide, and ... expanding customer base and improved costs, biodegradable polymers ... economically viable alternative to conventional polymers. Primary factors ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of ... This addition to the company’s industry-leading line of ... and available in 125 or 250 gallon capacities. ... weeks or less. , The new pre-engineered TerraPure tank ... existing TerraPure tank line – plus quick turnaround. ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... Biotech and pharma,companies are increasingly relying on ... Engineering & Biotechnology News (GEN). The,technique can provide ... drug,candidates for toxic effects, according to an article ... )., "Better screening technologies, noninvasive monitoring, and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) ... and preclinical studies of PX-866 were presented at ... Research (AACR) in,San Diego, held April 12-16, 2008. ... plans for these product candidates. Oncothyreon,is currently conducting ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... of Clinical Development as the,company prepares to enter ... the next 12 months., Dr. Goundis has ... of,clinical trials, including leadership positions at Speedel AG ...
Cached Biology Technology:Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays 2Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 2Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 3Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 4Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 5Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 3Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 4
(Date:9/16/2014)... at the Columbia Center for Children,s Environmental Health at ... to demonstrate an association between childhood asthma and prenatal ... of household products. Results appear online in the journal ... to mothers exposed during pregnancy to higher levels of ... had a 72 percent and 78 percent increase in ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
(Date:9/16/2014)... EUGENE, Ore. -- Each tree species has its own ... researchers and colleagues from other institutions who studied the ... growing on a Panamanian island. , "This study demonstrates ... plant families and with different ecological strategies possess very ... Steven W. Kembel, a former postdoctoral researcher in the ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2
... be difficult for a terrorist to obtain genes from the ... Armed with a fake email address, a would-be bioterrorist could ... online, and receive them by post within weeks. , That's ... the bioterror risks posed by the booming business of gene ...
... students have discovered the antler of an Irish Elk in cliffs ... the exact age of the antler has yet to be determined, ... lived around 11,000 years ago. The giant deer roamed the open ... of the last Ice Age, as the glaciers retreated northwards. ...
... Medical Institute researchers have discovered that pheromones essential for ... and not by the vomeronasal system, as researchers had ... epithelium, which was presumed to be mostly involved with ... pheromone detection. , Howard Hughes Medical Institute investigator ...
Cached Biology News:The bioweapon is in the post 2The bioweapon is in the post 3The bioweapon is in the post 4Students discover 11,000 year old remains of Irish Elk 2Olfactory system detects pheromones that control reproduction 2Olfactory system detects pheromones that control reproduction 3Olfactory system detects pheromones that control reproduction 4
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... offers the same benefits as the VSO valve ... is critical or flow is required below 600 ... of gas in proportion to the input current., ... width modulation; closed loop feedback delivers optimal system ...
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
... 96-well Filter Plates are offered in several ... um depth filter plates are ideal to ... Filtration is simple, versatile, and necessary to ... Captiva 10 um glass fiber and 20 ...
Biology Products: